More recently, with multiple trials such as EMPEROR-Reduced (49), EMPEROR-Preserved (50), DAPA-HF (51), and DAPA-CKD (52), even in the absence of T2DM, SGLT2 inhibition benefited patients with chronic kidney disease and patients with heart failure (with either reduced or preserved ejection fraction). This evidence concerns the gene SLC5A2 and heart failure.